Title: The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic
abnormalities in Brazilian patients with chronic hepatitis C
Version: 2 Date: 27 Dec 2020
Reviewer's report:
My previous comments have been addressed.
Regarding the association of the combined PNPLA3 + TM6Sf2 score: the section in the result
section on this is unclear (page 12, line 13):
'The HCV genotype was not associated with any of the liver histology parameters evaluated,
neither with the combination of TM6SF2 and PNPLA3 polymorphisms on logistic regression
analyses (significant liver fibrosis: p = 0.079; liver steatosis: p = 0.161). '
This reads as if you tested HCV genotype versus the TM6SF2+PNPLA3 combined score... but
this cannot be right? please clarify. Should it be:
'The HCV genotype was not associated with any of the liver histology parameters evaluated.
Likewise, the combination of TM6SF2 and PNPLA3 was not associated with liver fibrosis or
steatosis (p = 0.079 and p = 0.161, respectively).'
?
Title: The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic
abnormalities in Brazilian patients with chronic hepatitis C
Version: 2 Date: 27 Dec 2020
Reviewer's report:
My previous comments have been addressed.
Regarding the association of the combined PNPLA3 + TM6Sf2 score: the section in the result
section on this is unclear (page 12, line 13):
'The HCV genotype was not associated with any of the liver histology parameters evaluated,
neither with the combination of TM6SF2 and PNPLA3 polymorphisms on logistic regression
analyses (significant liver fibrosis: p = 0.079; liver steatosis: p = 0.161). '
This reads as if you tested HCV genotype versus the TM6SF2+PNPLA3 combined score... but
this cannot be right? please clarify. Should it be:
'The HCV genotype was not associated with any of the liver histology parameters evaluated.
Likewise, the combination of TM6SF2 and PNPLA3 was not associated with liver fibrosis or
steatosis (p = 0.079 and p = 0.161, respectively).'
?
Please review this paper.
user
Title: The role of PNPLA3 and TM6SF2 polymorphisms on liver fibrosis and metabolic
abnormalities in Brazilian patients with chronic hepatitis C
Version: 2 Date: 27 Dec 2020
Reviewer's report:
My previous comments have been addressed.
Regarding the association of the combined PNPLA3 + TM6Sf2 score: the section in the result
section on this is unclear (page 12, line 13):
'The HCV genotype was not associated with any of the liver histology parameters evaluated,
neither with the combination of TM6SF2 and PNPLA3 polymorphisms on logistic regression
analyses (significant liver fibrosis: p = 0.079; liver steatosis: p = 0.161). '
This reads as if you tested HCV genotype versus the TM6SF2+PNPLA3 combined score... but
this cannot be right? please clarify. Should it be:
'The HCV genotype was not associated with any of the liver histology parameters evaluated.
Likewise, the combination of TM6SF2 and PNPLA3 was not associated with liver fibrosis or
steatosis (p = 0.079 and p = 0.161, respectively).'
?
assistant